CD274 and neoplasm: Intrigued by our compelling results in the combination therapy involving CD244-deficient macrophages and anti-PD-L1 antibody, which demonstrated a significant reduction in tumor size compared to the control groups, we assert that the impact of CD244 removal in macrophages profoundly transforms the tumor immune microenvironment, holding clinical significance.